Loading...
•
Dec 31, 2024
Allogene Q4 2024 Earnings Report
Allogene reported a net loss and continued investment in CAR T therapies.
Key Takeaways
Allogene Therapeutics reported a Q4 2024 net loss of $59.9 million, with no revenue recognized for the quarter. The company ended the year with $373.1 million in cash and investments, projecting its cash runway into the second half of 2026. R&D expenses totaled $45.0 million, including $5.6 million in stock-based compensation, while general and administrative expenses were $15.5 million, including $7.3 million in stock-based compensation.
Net loss for Q4 2024 was $59.9 million, or $0.28 per share.
Cash, cash equivalents, and investments totaled $373.1 million at year-end.
R&D expenses were $45.0 million, driven by continued clinical trial progress.
Company expects its cash runway to fund operations into 2H 2026.
Allogene
Allogene
Forward Guidance
Allogene expects to continue advancing its pipeline while managing expenses and maintaining its projected cash runway into the second half of 2026.
Positive Outlook
- Strong cash position with $373.1M in cash and investments.
- Continued progress in CAR T therapy trials across multiple indications.
- Projected cash runway expected to support operations into 2H 2026.
- Ongoing strategic partnerships support development of MRD diagnostics.
- Phase 2 pivotal trial for cema-cel in LBCL continues to enroll patients.
Challenges Ahead
- Net loss of $59.9M in Q4, with no revenue recognized.
- Stock-based compensation expenses remain a significant cost factor.
- Cash burn expected to reduce cash holdings by approximately $170M in 2025.
- Uncertain regulatory timelines for key pipeline candidates.
- Market conditions for biotech funding remain challenging.